LSE:AZN - AstraZeneca remains a major FTSE 100 stock to watch because September 2026 has brought a busy mix of wins and setbacks for the drugmaker. On 1 September, it reported a positive Phase III lung cancer trial and a new European approval for Enhertu. Ten days later, its breast cancer medicine Etcamah missed the main goal of a large first-line trial.

Those headlines follow first-half results in July that showed Revenue up 9% and core Earnings Per Share up 12%, with full-year guidance maintained. The company has also changed how its shares trade in the US, replacing its American Depositary Shares with a direct New York Stock Exchange listing in February 2026. Importantly, its London Stock Exchange listing remains in place, and AstraZeneca is still a FTSE 100 constituent after FTSE Russell's September 2026 review.

Why AstraZeneca (AZN) Is in Focus

The most recent catalyst is pipeline news. On 11 September 2026, AstraZeneca said the SERENA-4 Phase III trial of Etcamah (camizestrant) plus palbociclib had not met its primary endpoint of a statistically significant improvement in progression-free survival, although a numerical improvement was seen. Yahoo Finance reported that US-listed shares fell 3% in after-hours trading.

Etcamah remains approved in the US, EU, Japan and other countries for a narrower group of patients whose tumours develop an ESR1 mutation during first-line treatment, based on the SERENA-6 trial. Susan Galbraith, executive vice president for oncology R&D, said: "Whilst we are disappointed by the SERENA-4 outcome, it sharpens our focus on maximising the number of patients who can benefit from Etcamah today based on SERENA-6 and reinforces the importance of ESR1 testing for patients on first-line therapy."

Earlier in the month, AstraZeneca announced positive Phase III results for Tagrisso combined with Orpathys in EGFR-mutated lung cancer, and European approval for Enhertu with pertuzumab in first-line HER2-positive metastatic breast cancer.

What Does AstraZeneca Do?

AstraZeneca is a global biopharmaceutical company headquartered in Cambridge, UK. It discovers, develops and sells prescription medicines across oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal, metabolism and respiratory treatments. The company operates in more than 125 countries.

Its sector is Pharmaceuticals & Biotechnology. The ordinary shares trade under the ticker AZN on the London Stock Exchange, Nasdaq Stockholm and, since 2 February 2026, the New York Stock Exchange.

Latest Developments for AZN

The listing change is one of the biggest structural developments of the year. AstraZeneca announced the plan in September 2025 and confirmed in January 2026 that its ordinary shares would begin trading directly on the NYSE on 2 February 2026. It withdrew its American Depositary Shares from Nasdaq while keeping its listings in London and Stockholm, a set-up it calls a "Harmonised Listing Structure".

The move gives US investors direct access to the ordinary shares without changing the company's UK headquarters. FTSE Russell's June and September 2026 reviews did not remove AstraZeneca from the FTSE 100.

US policy remains an important backdrop. In October 2025, AstraZeneca reached an agreement with the US government that included discounted direct-to-consumer pricing through TrumpRx and a three-year delay on Section 232 pharmaceutical tariffs. The company has committed $50bn to US Manufacturing and R&D over five years.

Financial Performance

For the six months to 30 June 2026, published on 27 July 2026, AstraZeneca reported:

  • Total revenue of $30,672m, up 9% (6% at constant exchange rates)
  • Product sales of $28,896m, up 8%
  • Core EPS of $5.21, up 12% (11% at constant exchange rates)
  • Reported EPS of $3.60, up 4%
  • An Interim Dividend raised by 3 cents to $1.06 per share

Second-quarter total revenue was $15,384m, and the core Operating Margin for the quarter was 34%. The company said growth was supported by double-digit increases in Oncology and Rare Disease.

Management maintained 2026 guidance for total revenue growth of a mid-to-high single-digit percentage and core EPS growth of a low double-digit percentage. Chief executive Pascal Soriot said the group remains "on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks".

Why the FTSE 100 Stock Could Stay in Focus

As one of the largest companies in the FTSE 100, AstraZeneca has a significant influence on the index. Movements in its share price can affect UK index funds, pension portfolios and the wider market mood.

The pipeline is a major driver. Soriot said the company has "more than twenty high-value readouts due over the next 18 months". Each result could change forecasts, as SERENA-4 has shown. The $80bn revenue ambition for 2030 also gives investors a clear long-term marker against which to judge progress.

The new US listing structure could also broaden the Shareholder base over time, although its long-term impact on trading in London is not yet clear.

Risks Investors Should Watch

Clinical risk is the most immediate. The SERENA-4 miss followed the CARDIO-TTRansform trial, which the company said in July had not met its primary endpoint. Further setbacks could weigh on revenue expectations.

US drug pricing and trade policy are also key risks. The United States is a large market for AstraZeneca, and changes to pricing rules, tariffs or reimbursement could affect profitability despite the 2025 agreement.

Other risks include competition, Patent expiries on older medicines, currency swings, since AstraZeneca reports in US dollars, and the cost of heavy Investment in research and manufacturing.

What Could Investors Watch Next?

AstraZeneca intends to publish its results for the nine months and third quarter of 2026 on 30 October 2026. Investors may watch whether revenue and core EPS remain on track for full-year guidance, as well as the performance of key oncology medicines.

Further trial readouts, regulatory decisions and data at medical conferences are likely to matter. Investors may also monitor trading volumes on the NYSE compared with London and any developments in US drug pricing policy.

Conclusion

AstraZeneca remains a major FTSE 100 stock to watch because it combines scale, a deep pipeline and exposure to fast-changing US policy. First-half results for the six months to 30 June 2026 showed solid revenue growth, higher core earnings and maintained guidance.

September has shown both sides of the Drug Development story, with a positive lung cancer trial and European approval followed by the SERENA-4 miss. The move to a direct NYSE listing has not changed its London listing or its FTSE 100 membership. With nine-month results due on 30 October 2026, pipeline news and guidance delivery are likely to remain in focus for the LSE-listed company.